// App-Quantinova.ai

: Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Researchers

Presenter

  • Ajai Chari

Principal Investigators

  • Maria-Victoria Mateos

  • Niels WCJ van de Donk

  • Jonathan L Kaufman

  • Philippe Moreau

  • Albert Oriol

  • Torben Plesner

  • Lotfi Benboubker

  • Hareth Nahi

  • Jie Tang

  • Peter Hellemans

  • Brenda Tromp

  • Pamela L Clemens

  • Andrew Farnsworth

  • Jesus F San-Miguel

  • Saad Z. Usmani

Medical Centers

  • Tisch Cancer Center, Mount Sinai School of Medicine, New York, NY

  • University Hospital of Salamanca, Salamanca, Spain

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • University Hospital Nantes, Nantes, France

  • ICO Institut Catala d'Oncologia, Barcelona, Spain

  • Vejle Hospital and University of Southern Denmark, Vejle, Denmark

  • Service dHematologie et Therapie Cellulaire, Hopital Bretonneau, Centre Hospitalier Regional Universitaire (CHRU), Tours, France

  • Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden

  • Janssen Research & Development, LLC, Raritan, NJ

  • Janssen Research & Development, Beerse, Belgium

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, High Wycombe, United Kingdom

  • Clinica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain

  • Levine Cancer Institute, Atrium Health, Charlotte, NC

Locations

  • United States

  • Spain

  • Netherlands

  • France

  • Denmark

  • Sweden

  • Belgium

  • United Kingdom

Companies

  • JB Medical Ltd.

  • Janssen Global Servi

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Methylprednisolone

  • Diphenhydramine

  • Derma-Pax lotion

  • Acetaminophen

  • daratumumab Intravenous

  • Montelukast

  • rHuPH20

  • Sparsentan

Outcome

  • N/A

Study Design

  • Open Label

  • Multinational

  • Multicenteric

Phase

  • I

Study Id's

  • NCT02519452

  • NCT03277105]

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved